Respicardia’s remedē® System Receives FDA Approval
Breakthrough Treatment of Moderate to Severe Central Sleep Apnea in Adult Patients Now Available
remedē News
Respicardia Closes $58.5 Million In Financing To Treat Central Sleep Apnea
Company announces strategic relationship with ZOLL Medical
Respicardia Announces Highmark Coverage for the remedē® System in Patients with Central Sleep Apnea
Expanded insurance coverage now available in Pennsylvania, Delaware and West Virginia
Respicardia Announces First U.S. Commercial Case With The remedē® System
Industry Veteran Peter Sommerness Joins as CEO to Lead U.S. Launch
Novant Health Forsyth Medical Center treats 25th patient with remedē
Respicardia, Inc. announced today that Novant Health Forsyth Medical Center in Winston-Salem, NC has treated its 25th patient with the remedē® System, an implantable device that treats central sleep apnea (CSA) by using phrenic nerve stimulation.